Why Research & Consulting Giant Gartner Shares Are Diving Tuesday

Gartner, Inc. (NYSE: IT) shares plummet as Q4 earnings report shows revenue growth in line with expectations but lower-than-anticipated guidance for 2024 triggers investor concern.

Gartner, Inc. (NYSE:IT) shares are trading lower after the company reported the fourth quarter of fiscal year 2023 results.

Quarterly revenue grew 5% year-on-year to $1.586 billion (+4% FX neutral), almost in line with the consensus of $1.585 billion.

Revenues from Research rose 6% year over year to $1.24 billion, and Conferences were $214 million, up 14% year over year. Consulting revenue fell 7% year over year to $128 million.

Global Technology Sales Contract Value rose 6% year over year FX Neutral to $3.7 billion. Global Business Sales Contract Value increased 13% year over year FX Neutral to $1.1 billion.

Adjusted EPS of $3.04 beat the consensus of $2.83.

Gartner generated $224 million in operating cash flow, +10% Y/Y. The company generated free cash flow of $196 million, +19% Y/Y.

CEO Gene Hall commented, “Entering 2024, our associate team is the best we’ve ever had, positioning us for long-term, sustained, double-digit growth. We are introducing guidance which is achievable across a wide range of economic scenarios, with the opportunity for upside.”

Outlook: Gartner issued FY24 adjusted EPS of at least $10.55 versus the $11.96 estimate. The company expects FY24 adjusted EBITDA of at least $1.435 billion.

Gartner expects 2024 total revenue of at least $6.24 billion against the consensus of $6.345 billion.

Price Action: IT shares traded lower by 7.83% at $433.00 premarket on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

Amicus Therapeutics Reports Preliminary 2023 Revenue And Provides 2024 Strategic Outlook; Q4 Revenue ~$115.1M Vs $112.25M Est.; Sees FY23 Revenue Of ~$399.4M Vs $396.45M Est.; Co Sees FY24 As First Full Year Of Achieving Non-GAAP Profitability

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "Last year was an incredible year for Amicus highlighted by the continued double-digit growth of Galafold sales and the global

FOLD

Read More

OLAPLEX Announces Leadership Transition; Amanda Baldwin, Seasoned Beauty Executive, To Serve As Chief Executive Officer, Effective By Early 2024; John P. “JP” Bilbrey, Executive Chair, To Serve As Interim Chief Executive Officer

Amanda Baldwin, Seasoned Beauty Executive, to Serve as Chief Executive Officer, Effective by Early 2024JuE Wong to Depart OLAPLEXJohn P. "JP" Bilbrey, Executive Chair, to Serve as Interim Chief Executive OfficerSANTA

OLPX